Original ArticlesControlled Pilot Study of Piracetam for Pediatric Opsoclonus–MyoclonusPranzatelli, Michael R.; Tate, Elizabeth D.; Galvan, Isabel; Wheeler, AlisaAuthor Information National Pediatric Myoclonus Center, Departments of Neurology and Pediatrics, Southern Illinois University School of Medicine, Springfield, Illinois, USA Address correspondence and reprint requests to Michael R. Pranzatelli, National Pediatric Myoclonus Center, SIU School of Medicine, PO Box 19658, Springfield, IL 62794–9658, USA. Clinical Neuropharmacology: November-December 2001 - Volume 24 - Issue 6 - p 352-357 Buy Abstract Piracetam is an effective symptomatic treatment for some types of myoclonus in adults. To survey the efficacy and safety of piracetam in pediatric opsoclonus–myoclonus, we conducted an open, randomized, two-period, dose-ranging, double-blind, crossover, clinical trial of five children comparing the antimyoclonic properties of oral piracetam to placebo. We devised and validated a new rating scale, specifically for pediatric opsoclonus–myoclonus. Two parents while blinded were able to identify the active phase by improvement in behavior, but another thought the behavior was worse. None of the patients showed improvement in myoclonus. The adult-equivalent dose of piracetam used in this study, which is threefold higher than that used in previous pediatric studies, was well tolerated and safe. We found our rating scale to be a reliable and useful tool for future studies of opsoclonus–myoclonus in children. © 2001 Lippincott Williams & Wilkins, Inc.